FOXO4-DRI

FOXO4-DRI is an experimental senolytic peptide studied for selective senescent-cell clearance through disruption of the FOXO4-p53 interaction.

Profile · 01

Overview

FOXO4-DRI, also called Proxofim in some research discussions, is a synthetic D-retro-inverso peptide engineered to disrupt the FOXO4-p53 interaction in senescent cells. It is not FDA-approved for any indication, and the evidence base remains preclinical.

The main idea is selective clearance of senescent cells rather than broad anabolic or anti-inflammatory signaling. Because no human clinical safety or efficacy data exist, this page should be treated as a highly experimental educational summary.

At a Glance

Goal
Study selective senescent-cell clearance and tissue-rejuvenation signaling in a research setting
Categories
SenolyticAnti-AgingLongevityCellular Health
Synergistic
Epitalon · GHK-Cu · Fisetin · Quercetin + Dasatinib
Profile · 02

Protocol

Suggested once-daily titration approach with escalation every four weeks.

Reconstitute
Add 3.0 mL bacteriostatic water to a 10 mg vial for about 3.33 mg/mL concentration
Typical daily range
250-500 mcg once daily
Start
250 mcg daily for Weeks 1-4
Target
500 mcg daily by Weeks 9-16
Frequency
Once per day (subcutaneous)
Cycle Length
8-16 weeks, then 4-8 weeks off before repeating
Timing
Any consistent time; rotate injection sites
Route
Subcutaneous
Cycle
8-16 weeks on, 4-8 weeks off

Inject once daily subcutaneously using a dilution that keeps measurements small but readable. All practical dosing discussion here is extrapolated from animal and mechanistic work rather than human trials. This is one of the most experimental entries in the library.

Dose progression

Weeks 1-4
250 mcg (0.25 mg) · 8 units (0.08 mL)
Weeks 5-8
375 mcg (0.375 mg) · 11 units (0.11 mL)
Weeks 9-12
500 mcg (0.5 mg) · 15 units (0.15 mL)
Weeks 13-16
500 mcg (0.5 mg) · 15 units (0.15 mL)

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Science · 01

How FOXO4-DRI works.

FOXO4-DRI is designed to disrupt the FOXO4-p53 interaction that helps senescent cells resist apoptosis. When that interaction is interrupted, p53 can relocate in a way that promotes senescent-cell death while ideally sparing healthy cells.

The D-retro-inverso design is used to explain improved peptide stability and resistance to proteolysis. Published support focuses on mouse and cell-model work, including landmark senolytic studies, not human trials.

Science · 02

Effects

Observations from clinical or preclinical literature.

Preclinical studies suggest selective clearance of senescent cells
Animal work reports improved tissue-homeostasis and fitness markers after senescent-cell removal
May reduce senescence-associated inflammatory signaling in preclinical settings
Human tolerability remains uncharacterized because no clinical trials are available
Mild injection-site irritation may occur
Long-term safety and off-target effects remain unknown
Science · 03

Caution

Avoid in active cancer or significant cancer history because senescence and tumor biology interactions are not fully characterized
Not recommended during pregnancy or breastfeeding because safety data is absent
Use caution in immunocompromised states because senescent-cell clearance may alter immune signaling
This peptide is fully experimental and should not be treated like a validated clinical therapy

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Lifestyle · 01

CoFactors

Fisetin
A natural senolytic discussed as complementary through a different pathway.
Quercetin
Often discussed in broader senolytic research stacks.
Vitamin C
Supports tissue repair and collagen biology after cellular turnover.
Omega-3 fatty acids
Support broader inflammatory balance as senescent-cell burden changes.
Lifestyle · 02

Life Factors

Complementary strategies for best outcomes.

Maintain a nutrient-dense diet rich in antioxidant and anti-inflammatory compounds
Use regular resistance and cardiovascular training to support cellular health
Prioritize sleep and stress management because both affect senescence-related biology
Avoid smoking and excessive alcohol because both accelerate cellular-aging pathways
Lifestyle · 03

Metrics

Day-to-day metrics worth tracking through the protocol.

  1. Energy and physical endurance - monitor for trend changes over time
  2. Inflammatory symptoms - track stiffness, recovery time, and broader resilience
  3. Skin quality and tissue recovery - note visible or functional changes cautiously
  4. Injection-site reactions - note redness, swelling, or discomfort
Lifestyle · 04

Labs

Baseline and periodic bloodwork to monitor systemic health during the protocol.

CRP (C-Reactive Protein)
General inflammatory marker for baseline and trend tracking.
IL-6
Relevant to discussion of SASP and inflammatory signaling if available.
CBC (Complete Blood Count)
General monitoring and immune-context screening.
CMP (Comprehensive Metabolic Panel)
Assess liver and kidney function during peptide use.
Testosterone
Some preclinical work reported changes in aged animals, though this is inferential in humans.
Calculators · 01

Supplies Calculator

Estimates assume the schedule defined for this peptide.

Length
Vial size
Bac. water
Syringe
Vials
0 × 10 mg each…
Syringes
0
Bac. water
0 mL
Swabs
02 per syringe
Calculators · 02

Dose Calculator

Dose Calculator

Vial
Bac. water
Syringe
Dose
Concentration
0mcg/mL
Volume per dose
0mL
…
Practice · 01

Preparation

Careful technique preserves potency. Solution should be clear — do not shake.

  1. Allow vial to reach room temperature for 15–20 minutes before reconstitution.
  2. Draw the chosen bacteriostatic water volume with a sterile syringe.
  3. Inject slowly down vial wall; avoid foaming.
  4. Gently swirl/roll until dissolved (do not shake).
  5. Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
  6. Use within 30 days; discard any unused solution after 30 days.
Practice · 02

Technique

General subcutaneous guidance from clinical best-practice resources.

Clean the vial stopper and injection site with alcohol and allow them to dry fully
Pinch a skinfold and insert the needle at 45-90 degrees into subcutaneous tissue
Do not aspirate for subcutaneous injections; inject slowly and steadily
Rotate sites across the abdomen, thighs, and upper arms to reduce local irritation
Discard used syringes immediately in a sharps container

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Practice · 03

Storage

Lyophilized
Store at room temp in dry, dark conditions; minimize moisture exposure.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles. Discard reconstituted vials after 30 days.

Notes

Allow vials to reach room temperature before opening to reduce condensation uptake.
Reference · 01

Notes

Use a new sterile insulin syringe for each injection and dispose of it safely
This protocol is built from preclinical literature only and has no human clinical-validation base
Document dose, timing, and perceived response carefully if used in a research context
FOXO4-DRI should be treated as highly experimental
PepTribe is an educational platform. This information is for research and learning purposes only and is not medical advice.
Reference · 02

References

  1. Cell (2017)
    Baar et al., targeted apoptosis of senescent cells and tissue-homeostasis restoration.
    https://doi.org/10.1016/j.cell.2017.02.031
  2. Communications Biology
    FOXO4-DRI-related senescent-cell apoptosis literature.
    https://www.nature.com/commsbio/
  3. Aging (Albany NY)
    FOXO4-DRI and aging-related preclinical observations.
    https://www.aging-us.com/
  4. Journal of Cellular and Molecular Medicine
    FOXO4-DRI work in fibrosis and myofibroblast models.
    https://onlinelibrary.wiley.com/journal/15824934
  5. CDC
    Subcutaneous injection route guidance.
    https://www.cdc.gov/vaccines/hcp/admin/downloads/YCTS-VaxAdmin-Subcut-injection.pdf
On this page